Literature DB >> 31768136

The Effect of Local Antibiogram-based Augmented Antibiotic Prophylaxis on Infection-related Complications Following Prostate Biopsy.

Raoul S Concepcion1,2, Edward M Schaeffer3, Neal D Shore4, Deepak A Kapoor5,6, Jeffrey A Scott1, Gary M Kirsh7.   

Abstract

Given the number of prostate biopsies performed annually in the United States and associated infectious events as a result, we sought to determine if implementation of a standardized biopsy protocol utilizing antibiotic prophylaxis based on locally derived antibiograms would result in a decrease, relative to a contemporary control population, in the incidence of infection-related complications among community-based practices. A total of nine member groups of LUGPA participated in both a retrospective review and a prospective study of infection-related complications following prostate biopsy. Historic infectious complications, defined as chills/rigor, temperature higher than 101 °F, or documented positive blood or urine cultures, were self-reported by a retrospective review of patients undergoing prostate biopsy under the practice's current protocol in the year prior to the study. The prospective phase of the study required each group to develop a locally derived augmented prophylaxis regimen (>2 antibiotics) based on local antibiograms. After implementation, the practices enrolled patients undergoing prostate biopsy over an 8-week period. Monitoring for infection-related complication took place over the ensuing 3 weeks post-biopsy. Seven hundred fifty-nine patients over nine practices were enrolled into the study utilizing the augmented locally determined prophylaxis protocol. There was a 53% reduction in the incidence of infection-related complication, relative to the historical rate. By developing a standardized biopsy protocol with specific emphasis on incorporating an augmented antibiotic prophylactic regimen based upon local antibiograms, we were able to demonstrate in a prospective trial across nine geographically distinct community practices a significant reduction in the incidence of infection-related complications.
© 2019 MedReviews®, LLC.

Entities:  

Keywords:  Antibiogram; Biopsy; Drug-resistant bacteria; Prophylaxis, antibiotic; Prostate

Year:  2019        PMID: 31768136      PMCID: PMC6864918     

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


  16 in total

1.  Predictors of Infectious Complications after Targeted Prophylaxis for Prostate Needle Biopsy.

Authors:  Dimitri Papagiannopoulos; Michael Abern; Nathaniel Wilson; Nicholas O'Block; Lester Raff; Christopher Coogan; Kalyan C Latchamsetty
Journal:  J Urol       Date:  2017-08-12       Impact factor: 7.450

2.  Reducing Infectious Complications Following Transrectal Ultrasound-guided Prostate Biopsy: A Systematic Review.

Authors:  Jordon T Walker; Nirmish Singla; Claus G Roehrborn
Journal:  Rev Urol       Date:  2016

3.  Risk factors for fluoroquinolone-resistant Escherichia coli in adults with community-onset febrile urinary tract infection.

Authors:  Willize E van der Starre; Cees van Nieuwkoop; Sunita Paltansing; Jan W van't Wout; Geert H Groeneveld; Martin J Becker; Ted Koster; G Hanke Wattel-Louis; Nathalie M Delfos; Hans C Ablij; Eliane M S Leyten; Jeanet W Blom; Jaap T van Dissel
Journal:  J Antimicrob Chemother       Date:  2010-12-01       Impact factor: 5.790

4.  Prevalence and significance of fluoroquinolone resistant Escherichia coli in patients undergoing transrectal ultrasound guided prostate needle biopsy.

Authors:  Michael A Liss; Alexandra Chang; Rosanne Santos; Amy Nakama-Peeples; Ellena M Peterson; Kathryn Osann; John Billimek; Richard J Szabo; Atreya Dash
Journal:  J Urol       Date:  2011-02-22       Impact factor: 7.450

5.  National Trends in Prostate Biopsy and Radical Prostatectomy Volumes Following the US Preventive Services Task Force Guidelines Against Prostate-Specific Antigen Screening.

Authors:  Joshua A Halpern; Jonathan E Shoag; Amanda S Artis; Karla V Ballman; Art Sedrakyan; Dawn L Hershman; Jason D Wright; Ya Chen Tina Shih; Jim C Hu
Journal:  JAMA Surg       Date:  2017-02-01       Impact factor: 14.766

6.  Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy.

Authors:  Robert K Nam; Refik Saskin; Yuna Lee; Ying Liu; Calvin Law; Laurence H Klotz; D Andrew Loblaw; John Trachtenberg; Aleksandra Stanimirovic; Andrew E Simor; Arun Seth; David R Urbach; Steven A Narod
Journal:  J Urol       Date:  2010-01-20       Impact factor: 7.450

Review 7.  Active surveillance for prostate cancer: current evidence and contemporary state of practice.

Authors:  Jeffrey J Tosoian; H Ballentine Carter; Abbey Lepor; Stacy Loeb
Journal:  Nat Rev Urol       Date:  2016-03-08       Impact factor: 14.432

8.  Complication rate of transrectal ultrasound guided prostate biopsy: a comparison among 3 protocols with 6, 10 and 15 cores.

Authors:  Andreas P Berger; Christian Gozzi; Hannes Steiner; Ferdinand Frauscher; John Varkarakis; Hermann Rogatsch; Georg Bartsch; Wolfgang Horninger
Journal:  J Urol       Date:  2004-04       Impact factor: 7.450

9.  Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.

Authors:  H Gilbert Welch; Peter C Albertsen
Journal:  J Natl Cancer Inst       Date:  2009-08-31       Impact factor: 13.506

Review 10.  Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success.

Authors:  Liam S Redgrave; Sam B Sutton; Mark A Webber; Laura J V Piddock
Journal:  Trends Microbiol       Date:  2014-05-16       Impact factor: 17.079

View more
  2 in total

1.  Therapeutic failures of targeted antibiotic prophylaxis in urology.

Authors:  Elodie Curlier; Yvanne Sadreux; Samuel Markowicz; Laurent Brureau; Sunniva Donat; Pascal Blanchet; Pierre-Marie Roger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-11-17       Impact factor: 3.267

Review 2.  [Infectious complications following prostate biopsy-Major changes 2020].

Authors:  A Pilatz; G Bonkat; F Wagenlehner
Journal:  Urologe A       Date:  2020-12       Impact factor: 0.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.